Related Experiment Video

Updated: Dec 9, 2025

Improved Registration of 3D CT Angiography with X-ray Fluoroscopy for Image Fusion During Transcatheter Aortic Valve Implantation
06:59

Improved Registration of 3D CT Angiography with X-ray Fluoroscopy for Image Fusion During Transcatheter Aortic Valve Implantation

Published on: June 3, 2018

10.9K

Preprocedural circulating galectin-3 and the risk of mortality after transcatheter aortic valve replacement: a

Hong-Liang Zhang1, Guang-Yuan Song1, Jie Zhao1

  • 1Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Beilishi Road 167, Xicheng District, Beijing 100037, China.

Bioscience Reports
|September 7, 2020
PubMed

Insights

Higher galectin-3 levels before transcatheter aortic valve replacement (TAVR) predict mortality in patients with aortic stenosis (AS). This meta-analysis confirms galectin-3 as a significant predictor of all-cause mortality post-TAVR.

Area of Science:

  • Cardiology
  • Biomarkers
  • Interventional Cardiology

Background:

  • Galectin-3 is a potential biomarker for predicting mortality in patients with aortic stenosis (AS).
  • Previous studies on galectin-3 and mortality after transcatheter aortic valve replacement (TAVR) yielded inconsistent results.
  • A comprehensive meta-analysis is needed to clarify the association.

Purpose of the Study:

  • To evaluate the association between baseline circulating galectin-3 levels and mortality in patients undergoing TAVR.
  • To synthesize evidence from existing prospective cohort studies through meta-analysis.

Main Methods:

  • Systematic literature search of PubMed, Cochrane's Library, and Embase databases.
  • Meta-analysis of five prospective cohort studies including 854 patients.
  • Fixed- and random-effects models were employed, with subgroup analyses to assess study characteristic influences.

Main Results:

  • Higher baseline galectin-3 was associated with an increased risk of all-cause mortality after TAVR (RR: 1.63, P=0.002).
  • This association remained significant after adjusting for estimated glomerular filtration rate or B-type natriuretic peptide (BNP).
  • A trend towards a stronger association was observed with enzyme-linked fluorescent assay (ELFA) compared to enzyme-linked immunosorbent assay (ELISA) methods.

Conclusions:

  • Elevated circulating galectin-3 levels prior to TAVR may serve as a significant predictor of all-cause mortality in AS patients.
  • Galectin-3 is a valuable prognostic biomarker in the context of TAVR outcomes.
  • Further research may explore the impact of assay methods on the predictive value of galectin-3.
Abstract

Keywords:
Aortic stenosisGalectin-3Meta-analysisMortalityTranscatheter aortic valve replacement

More Related Videos

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat04:30

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat

Published on: February 4, 2021

3.6K
Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels08:12

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels

Published on: May 26, 2023

2.0K

Related Concept Videos

Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
217
Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
150